Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$10.4M Sell
29,635
-36
-0.1% -$12.8K 2.95% 12
2025
Q4
$9.71M Buy
29,671
+85
+0.3% +$27K 2.88% 10
2025
Q3
$8.35M Sell
29,586
-270
-0.9% -$78.3K 2.57% 14
2025
Q2
$8.34M Sell
29,856
-1,018
-3% -$288K 2.73% 15
2025
Q1
$9.62M Sell
30,874
-503
-2% -$149K 3.23% 8
2024
Q4
$8.18M Buy
31,377
+73
+0.2% +$21.7K 2.66% 13
2024
Q3
$10.1M Sell
31,304
-1,101
-3% -$360K 3.14% 4
2024
Q2
$10.1M Buy
32,405
+3,248
+11% +$954K 3.21% 5
2024
Q1
$8.29M Sell
29,157
-165
-0.6% -$48.3K 2.73% 10
2023
Q4
$8.45M Buy
29,322
+1,224
+4% +$334K 2.97% 7
2023
Q3
$7.55M Buy
28,098
+869
+3% +$217K 2.76% 10
2023
Q2
$6.05M Sell
27,229
-279
-1% -$64.7K 2.1% 21
2023
Q1
$6.65M Buy
27,508
+560
+2% +$137K 2.49% 12
2022
Q4
$7.08M Sell
26,948
-51,307
-66% -$13.8M 2.68% 11
2022
Q3
$17.6M Buy
78,255
+52,903
+209% +$12.8M 2.34% 13
2022
Q2
$6.17M Buy
25,352
+305
+1% +$74.7K 2.33% 14
2022
Q1
$6.06M Buy
25,047
+97
+0.4% +$22.3K 2% 18
2021
Q4
$5.61M Sell
24,950
-13
-0.1% -$2.74K 1.84% 26
2021
Q3
$5.31M Buy
24,963
+184
+0.7% +$42.4K 1.94% 24
2021
Q2
$6.04M Buy
24,779
+534
+2% +$131K 2.16% 15
2021
Q1
$6.03M Sell
24,245
-55
-0.2% -$13.1K 2.39% 13
2020
Q4
$5.59M Buy
24,300
+130
+0.5% +$30K 2.3% 14
2020
Q3
$6.14M Sell
24,170
-485
-2% -$120K 2.92% 7
2020
Q2
$5.82M Buy
24,655
+115
+0.5% +$26.2K 3.08% 5
2020
Q1
$4.97M Sell
24,540
-160
-0.6% -$34.9K 3.31% 7
2019
Q4
$5.96M Sell
24,700
-475
-2% -$105K 3.02% 6
2019
Q3
$4.87M Buy
25,175
+370
+1% +$71K 2.61% 9
2019
Q2
$4.57M Buy
24,805
+387
+2% +$69.3K 2.4% 12
2019
Q1
$4.64M Buy
24,418
+570
+2% +$109K 2.34% 11
2018
Q4
$4.64M Buy
+23,848
New +$4.65M 2.77% 7

Other funds holding AMGN

O'Brien Greene & Co's AMGN Position: Q1 2026 in Review

O'Brien Greene & Co reduced its Amgen (AMGN) stake by 0.12% in Q1 2026, selling an estimated $12.8K and leaving 29,635 shares worth $10.4M. The position accounts for 2.95% of the portfolio, ranked #12.

O'Brien Greene & Co first reported a position in AMGN in Q4 2018 and has held it in 30 quarters since. The position peaked at $17.6M in Q3 2022. 3,126 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.

  • O'Brien Greene & Co held 29,635 shares of Amgen worth $10.4M as of Q1 2026.
  • O'Brien Greene & Co sold 36 Amgen shares in Q1 2026, an estimated $12.8K.
  • Amgen made up 2.95% of O'Brien Greene & Co's portfolio in Q1 2026, its #12 holding.
  • O'Brien Greene & Co first reported a position in Amgen in Q4 2018 and has held it in 30 quarters since.
  • O'Brien Greene & Co's Amgen position peaked at $17.6M in Q3 2022.
  • 3,126 funds tracked by Wall St. Rank held Amgen as of Q1 2026.

Based on O'Brien Greene & Co's 13F filing for Q1 2026, filed 6 May 2026.